Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027923 | 1.00 | GABRR1 (0.34) | GABRR1CYP1A2BTN3A1ALDH1A1FOLH1 | |
| SCHEMBL5027924 | 1.00 | GABRR1 (0.34) | GABRR1CYP1A2BTN3A1ALDH1A1FOLH1 | |
| SCHEMBL16840474 | 0.84 | TSHR (0.31) | BTN3A1 | |
| SCHEMBL26478528 | 0.82 | — | — | |
| SCHEMBL30664718 | 0.82 | — | — | |
| SCHEMBL12858172 | 0.81 | GABRR1 (0.41) | GABRR1CYP1A2BLM | |
| SCHEMBL1751319 | 0.81 | BTN3A1 (0.35) | BTN3A1 | |
| SCHEMBL2670209 | 0.81 | BTN3A1 (0.35) | BTN3A1 | |
| SCHEMBL2670343 | 0.81 | BTN3A1 (0.35) | BTN3A1 | |
| SCHEMBL2719334 | 0.80 | PGK1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117917416-A | KRAS G12D degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-117917410-A | Pan-KRAS degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-0229384-B1 | Beta-lactam compounds and their production | SUMITOMO PHARMA (JP) | 1994-08-10 | — | — | EP | disclosed |
| US-5134231-A | Chemical intermediates for 1-alkylcarbapenem compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-07-28 | — | — | US | disclosed |
| US-4892961-A | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0210657-B1 | AMINO ACID DERIVATIVES, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| WO-1988001619-A1 | 1'-METHYL-BETA-LACTAM COMPOUNDS AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-03-10 | — | — | WO | disclosed |
| EP-0229384-A2 | Beta-lactam compounds and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-07-22 | — | — | EP | disclosed |
| EP-0210657-A1 | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | GABRR1 4017/4885CYP1A2 4095/4885BTN3A1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.